HR and neoplasm: In case of a co-expression of HR and HER2 the tumor was included in the HR+/HER2+ category (13 cases, 11.2%), while tumors negative for ER, PgR and HER2 were designated as HR-/HER2- (triple negative, 33 cases, 28.4%).